The brain occupies a privileged immunological and biochemical niche. It is separated from the systemic circulation by a tight barrier that excludes most molecules in the bloodstream while admitting essential nutrients through specific transporters. This blood-brain barrier (BBB) protects the brain from toxins, pathogens, and large fluctuations in plasma composition, but it also restricts the delivery of drugs and immune cells. Many of the central problems of neurological therapeutics — getting antibiotics into the CSF in meningitis, delivering chemotherapy to brain tumors, achieving adequate drug levels in Parkinson disease — are fundamentally problems of crossing the BBB. Understanding its structure, function, and pathology is therefore a prerequisite to understanding CNS pharmacology and CNS disease.

This page covers the cellular structure of the BBB, the transport mechanisms that supply the brain with what it needs, the circumventricular organs where the barrier is incomplete by design, and the diseases that disrupt the barrier with clinical consequences.

The Neurovascular Unit

The blood-brain barrier is not a single membrane but a coordinated system of cells, the neurovascular unit:

• Endothelial cells of brain capillaries, joined by tight junctions that prevent paracellular leak. These tight junctions are the principal physical barrier.
• Pericytes embedded in the basement membrane, regulating capillary blood flow and supporting endothelial barrier function.
• Astrocyte endfeet wrapping around the capillaries, contributing signaling and structural support to the barrier.
• Basement membrane between the endothelium and astrocyte endfeet.
• Neurons whose activity drives local blood flow through neurovascular coupling.
• Microglia contributing to immune surveillance.

The neurovascular unit functions as a whole. Damage to any of these components disrupts the barrier and produces leak of plasma components into the brain — the basis of vasogenic edema in stroke, tumors, and inflammation.

Structural Features That Make the BBB Tight

Brain capillary endothelium differs from systemic endothelium in several ways:

• Tight junctions: composed of claudins, occludins, and zonula occludens proteins. Far more extensive and less permeable than the junctions in systemic capillaries.
• Few transcellular vesicles: systemic endothelium uses vesicular transport (transcytosis) to move plasma proteins; brain endothelium has fewer such vesicles.
• No fenestrations: holes in the endothelial membrane that admit small molecules in many systemic capillaries are absent in the brain (except in the circumventricular organs).
• Active efflux transporters: P-glycoprotein, BCRP, and several others actively pump many drugs out of the brain back into the bloodstream, further limiting brain penetration of orally administered medications.

The result: the BBB is essentially impermeable to most polar molecules, charged molecules, large molecules, and protein-bound molecules.

What Crosses the BBB

Diffusion

Small, lipid-soluble molecules can diffuse across the endothelial membrane. Examples: oxygen, carbon dioxide, ethanol, many anesthetics, many antidepressants.

Carrier-Mediated Transport

Specific transporters carry essential nutrients across the BBB:

• GLUT1 (glucose transporter 1): highly expressed on brain endothelium, transports glucose. GLUT1 deficiency syndrome (autosomal dominant mutations) produces seizures, intellectual disability, and movement disorders responsive to the ketogenic diet (ketones use a different transport mechanism).
• L-system amino acid transporter (LAT1): transports large neutral amino acids including phenylalanine, leucine, valine. Used by levodopa, methyldopa, baclofen, and gabapentin to enter the brain.
• Monocarboxylate transporter (MCT1): transports lactate, pyruvate, and ketone bodies. Important in the metabolic flexibility of the brain.
• Various other transporters: for choline, vitamins, peptides.

Receptor-Mediated Transcytosis

Specific large molecules cross via receptor-mediated transcytosis. Examples: transferrin (for iron delivery), insulin, leptin. This pathway has been exploited to deliver therapeutic agents conjugated to receptor ligands.

Active Efflux

Many molecules that enter the brain are actively pumped out by efflux transporters. P-glycoprotein (MDR1) is the most studied; it pumps out many drugs including some opioids, some anticonvulsants, antiretrovirals, and chemotherapy agents. P-glycoprotein expression at the BBB is one reason why oral chemotherapy is often ineffective against brain tumors.

The Blood-CSF Barrier

A second barrier exists between the blood and the cerebrospinal fluid: the choroid plexus epithelium. The choroid plexus consists of a tuft of capillaries (which are fenestrated and permeable, unlike brain capillaries) covered by a specialized cuboidal epithelium with tight junctions. The tight junctions of the choroid plexus epithelium are the blood-CSF barrier, controlling what enters the CSF from the choroidal blood.

The blood-CSF barrier is not identical to the BBB. Some molecules cross one barrier but not the other. Drug levels in CSF and in brain parenchyma can differ substantially.

Glymphatic Clearance and Meningeal Lymphatics

In addition to the BBB and the blood-CSF barrier, current models of CNS fluid homeostasis include two clearance pathways that were not part of the classical picture:

• Glymphatic system: a perivascular network — first described by Iliff and Nedergaard in 2012 — in which CSF enters the brain along periarterial spaces, mixes with interstitial fluid through aquaporin-4 channels on astrocytic endfeet, and is cleared along perivenous spaces. The system appears most active during sleep and is implicated in clearance of interstitial solutes including amyloid-β.
• Meningeal lymphatics: functional lymphatic vessels described by Louveau, Aspelund, and colleagues in 2015, running along the dural venous sinuses (especially the superior sagittal and transverse sinuses) and draining CSF-derived fluid and immune cells to deep cervical lymph nodes. Their existence overturned the long-held view that the CNS had no lymphatic drainage.

The exact physiology and clinical relevance in humans are still being refined, but these pathways are now an important part of modern CSF and waste-clearance models — with potential implications for neurodegeneration (amyloid clearance), neuroinflammation (CNS immune surveillance), traumatic brain injury, and idiopathic intracranial hypertension. The classical “no lymphatics in the CNS” teaching is no longer accurate.

The Circumventricular Organs

Several small regions of the brain lack a normal BBB by design — they have fenestrated capillaries that allow plasma to communicate with brain interstitial fluid. These circumventricular organs (CVOs) serve as the brain’s sensors and effectors for systemic signals:

• Area postrema (medulla, floor of fourth ventricle): the chemoreceptor trigger zone, sensing circulating emetic stimuli (toxins, cytokines, drugs) and inducing vomiting.
• Organum vasculosum of the lamina terminalis (OVLT): senses plasma osmolality; signals to the hypothalamus to regulate vasopressin release and thirst.
• Subfornical organ: senses circulating angiotensin II; signals to regulate fluid balance and blood pressure.
• Median eminence: where hypothalamic neurosecretory cells release hormones into the portal circulation to control the anterior pituitary.
• Neurohypophysis (posterior pituitary): where vasopressin and oxytocin are released into the systemic circulation.
• Pineal gland: secretes melatonin.
• Subcommissural organ: function unclear.

The CVOs are the windows through which the brain monitors the systemic milieu and through which it sends humoral signals back. The lack of a BBB at these sites is not a bug but a feature.

BBB Dysfunction in Disease

Stroke

Acute ischemia disrupts the BBB. Initially, the increased permeability is patchy; over hours to days it becomes more diffuse. The resulting vasogenic edema increases mass effect and can cause secondary injury. Mannitol and hypertonic saline are used to reduce edema by drawing water out of the brain across the partially intact BBB. tPA increases the risk of hemorrhagic transformation in part because it acts in regions where the BBB is compromised.

Tumors

Brain tumors disrupt the local BBB through angiogenesis (new vessels that lack tight junctions) and through inflammatory cytokines. The leaky tumor vasculature is what allows contrast enhancement on MRI — gadolinium leaks from blood into the tumor interstitium where the BBB is disrupted. The same leak allows steroids to reduce peritumoral edema dramatically.

Infection

Meningitis and encephalitis disrupt the BBB through cytokine release, neutrophil migration, and direct pathogen effects. The increased permeability allows antibiotics to penetrate the CNS at higher concentrations than in healthy brain (a clinically important point in choosing antibiotic doses). Tuberculous meningitis and cryptococcal meningitis can produce more profound and persistent BBB disruption.

Multiple Sclerosis

BBB disruption is a fundamental feature of MS plaques. Active plaques show gadolinium enhancement on MRI because of leaky blood vessels; older inactive plaques do not enhance. The BBB disruption may be either a primary event (initiating the inflammatory cascade) or a secondary consequence of inflammation; the question remains debated.

Seizures

Status epilepticus and prolonged seizures disrupt the BBB locally. This may contribute to ongoing seizure susceptibility (a partial substrate for “kindling”) and may be relevant to post-status complications.

Hypertensive Encephalopathy and PRES

Severe hypertension exceeds the BBB’s ability to maintain itself, producing vasogenic edema preferentially in the posterior cerebrum — posterior reversible encephalopathy syndrome (PRES). Causes include malignant hypertension, eclampsia, cyclosporine and tacrolimus toxicity, and various other conditions. The clinical picture: headache, visual symptoms, seizures, sometimes encephalopathy. MRI shows characteristic posterior white matter edema. Often reversible with treatment of the underlying cause.

Aging

BBB function declines with age. Subtle BBB leak in the hippocampus has been documented in older adults and may contribute to Alzheimer disease pathogenesis. Whether this is cause or consequence remains debated.

Drug Delivery to the CNS

The BBB is the main pharmacokinetic challenge in CNS therapeutics. Strategies to overcome it:

• Lipophilic drug design: small lipid-soluble drugs can diffuse across the BBB. Many CNS-active drugs are designed this way.
• Prodrugs: precursors that are transported across the BBB and then converted to the active drug. Levodopa is the classic example — dopamine cannot cross the BBB, but levodopa can, using the LAT1 transporter.
• Transporter targeting: drugs designed to be substrates of CNS transporters.
• Inhibition of efflux transporters: blocking P-glycoprotein to keep drugs in the brain (experimental).
• Intrathecal administration: bypassing the BBB by injecting directly into CSF. Used for chemotherapy in leptomeningeal disease, for baclofen pump in spasticity, for some forms of intrathecal antibiotics, for spinal anesthesia.
• Focused ultrasound: transient, controlled disruption of the BBB at a defined location to allow drug entry. An experimental approach with growing clinical interest.
• Convection-enhanced delivery: direct intracerebral infusion of drugs through a catheter, used in experimental neuro-oncology.
• Carrier proteins or nanoparticles: conjugating drugs to ligands of BBB receptors (transferrin, insulin) to enable receptor-mediated transcytosis. Experimental.

Antibiotic Penetration

Antibiotic CSF penetration varies enormously. Some examples:

Inflammation of the meninges (as in meningitis) increases BBB permeability and improves penetration of many antibiotics that do not cross well in healthy brain. This is why “meningitis doses” of beta-lactams are often higher than the doses used for other infections.

🔍 Did You Know?

The dopamine that is administered intravenously to support blood pressure in critically ill patients does not cross the BBB. The clinical implication: intravenous dopamine has cardiovascular effects but no central nervous system effects. By contrast, levodopa — the immediate metabolic precursor of dopamine — does cross the BBB using the LAT1 amino acid transporter. Once across, it is decarboxylated to dopamine within nigrostriatal neurons, providing the neurotransmitter that has been lost in Parkinson disease. Carbidopa, given alongside levodopa, inhibits peripheral decarboxylation (it does not cross the BBB itself), preserving levodopa for central conversion and reducing peripheral side effects.

Pitfalls and Pearls

• The BBB is a neurovascular unit, not just an endothelial barrier. Astrocytes, pericytes, and neurons all contribute to its function.
• Tight junctions and active efflux transporters are the principal mechanisms of BBB exclusion.
• The circumventricular organs lack a BBB by design — these are the sensory and effector windows between brain and systemic circulation.
• Gadolinium enhancement on MRI marks BBB disruption — active MS plaques, tumors, abscesses, acute infarcts.
• Levodopa crosses the BBB; dopamine does not. This single fact is the cellular basis of Parkinson disease pharmacotherapy.
• Antibiotic CSF penetration improves with meningeal inflammation, but starting doses for meningitis are often higher to ensure adequate concentrations.
• P-glycoprotein and other efflux transporters limit brain penetration of many drugs. This explains some treatment failures despite adequate plasma levels.
• Intrathecal administration bypasses the BBB: used for baclofen in severe spasticity, for chemotherapy in leptomeningeal disease, for some antibiotics, for spinal anesthesia.
• PRES classically affects the posterior cerebrum — occipital and posterior parietal white matter — and is often reversible with treatment of the underlying cause.
• BBB dysfunction in aging may contribute to neurodegenerative disease. Research is ongoing.

References

1. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37(1):13-25.
2. Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1):a020412.
3. Banks WA. From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery. Nat Rev Drug Discov. 2016;15(4):275-292.
4. Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133-150.
5. Nau R, Sörgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23(4):858-883.
6. Bartynski WS. Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008;29(6):1036-1042.
7. Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012;4(147):147ra111.
8. Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523(7560):337-341.
9. Aspelund A, Antila S, Proulx ST, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. J Exp Med. 2015;212(7):991-999.